Pharmaceuticals

LB Pharmaceuticals

LB Pharmaceuticals released FY2026 Q1 earnings on May 12 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.6746 (forecast USD -0.745)

LB Pharmaceuticals released FY2025 Annual Earnings on March 26 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -3.1329 (forecast USD -4.0275)

LB Pharmaceuticals released FY2025 Q4 earnings on March 26 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.4515 (forecast USD -0.4475)

LB Pharmaceuticals released FY2025 9 Months Earnings on November 6, 2025 (EST) with actual revenue of USD 0 and EPS of USD -40.5593

LB Pharmaceuticals released FY2025 Q3 earnings on November 6, 2025 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.6123 (forecast USD -0.57)

LB Pharmaceuticals' LB-102 Earns Buy Rating, Shows Great Potential

Pontifax Management 4 G.P. (2015) Ltd. Announced Acquisition of LB Pharmaceuticals Inc. Common Stock

LB Pharmaceuticals Inc. released FY2024 Semi-Annual Earnings on August 22, 2025 (EST) with actual revenue of USD 0 and EPS of USD 0

LB Pharmaceuticals released FY2025 Semi-Annual earnings on August 22 (EST), actual revenue USD 0, actual EPS USD -40.4187

LB Pharmaceuticals released FY2025 Q2 earnings on August 22 (EST), actual revenue USD 0, actual EPS USD -20.2093

LB Pharmaceuticals released FY2024 Q4 earnings on August 22 (EST), actual revenue USD 0, actual EPS USD -14.1157

LB Pharmaceuticals Inc. released FY2024 Q2 earnings on August 22, 2025 (EST) with actual revenue of USD 0 and EPS of USD 0

LB Pharmaceuticals released FY2025 Q1 earnings on August 22, 2025 (EST) with actual revenue of USD 0 and EPS of USD -14.7891

LB Pharmaceuticals released FY2024 Q3 earnings on August 22 (EST), actual revenue USD 0, actual EPS USD -39.4927

LB Pharmaceuticals released FY2024 Annual Earnings on August 22 (EST), actual revenue USD 0, actual EPS USD -176.1498

LB Pharmaceuticals released FY2023 Annual Earnings on August 22 (EST), with actual revenue of USD 0 and EPS of USD -25.1395

Amesite

InMed Pharmaceuticals

Meiwu Tech

Co-Diagnostics

Phoenix Asia

Generation Income Properties

Rubico

MetaVia

Virax Biolabs

Agilysys

LBRX

Craig-Hallum analyst Adam Vogel has reaffirmed a Buy rating on LB Pharmaceuticals, Inc. (LBRX) with a price target of $36.00. Vogel, a 4-star analyst with a 32.2% average return and 94.12% success rate, focuses on the Healthcare sector. Additionally, Piper Sandler also maintains a Buy rating on LBRX, setting a higher price target of $78.00.

Tip Ranks

Aclaris Therap

Immunome

Piper Sandler Cos

Craig-Hallum Keeps Their Buy Rating on LB Pharmaceuticals, Inc. (LBRX)

Earnings Watch

LB Pharmaceuticals | 8-K: FY2026 Q1 Revenue: USD 0

LTRN

SBIO

LTR Pharma has announced positive interim Phase II clinical data for its SPONTAN intranasal PDE5 therapy, showing a median time to maximum plasma concentration of 10 minutes for the 5 mg dose. The company is pursuing a dual US strategy for erectile dysfunction treatments, targeting FDA 505(b)(2) pathway for SPONTAN and earlier market entry for ROXUS. With $24.1 million in cash and no debt, LTR Pharma is well-positioned to fund operations and reach key milestones, although regulatory execution risks remain.

Small Caps

Lantern Pharma

ALPS Medical Breakthrough

Invesco Nasdaq Biotechnology ETF

VanEck Biotech ETF

Direxion S&P Biotech Bull 3X

Proshares Ultra Nasdaq Biotech

First Trust NYSE Arca Biotech Index Fd

Ark Genomic Revolution ETF

iShares US Pharma

iShares Biotechnology ETF

Invesco Biotechnology & Genome ETF

SPDR S&P Biotech

AptarGroup

Mayne Pharma Group Limited

LTR Pharma Unveils Strong SPONTAN Data and Dual US Strategy

BLRX

BioLineRx shares are trading higher after the company announces that the first patient has been dosed in its Phase 1/2A study of GLIX-1 for glioblastoma and other high-grade gliomas.

benzinga_article

Bioline RX

Top Wall Street analysts have initiated coverage on several companies with bullish ratings. Stephen Richardson from Evercore ISI rated HMH Holding Inc (NASDAQ:HMH) as Outperform with a price target of $27. Raghuram Selvaraju from HC Wainwright rated LB Pharmaceuticals Inc (NASDAQ:LBRX) as Buy with a target of $45. Allen Lutz from B of A Securities rated Guardian Pharmacy Services Inc (NYSE:GRDN) as Buy with a target of $42. Selvaraju also rated NervGen Pharma Corp (NASDAQ:NGEN) as Buy with a target of $18. HMH shares closed at $20.13, LBRX at $30.73, GRDN at $37.57, and NGEN at $3.92 on Friday.

Guardian Pharmacy Services

NervGen Pharma

This LB Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

LB Pharmaceuticals Inc's investigational therapy LB-102 has shown positive Phase 2 results in treating acute schizophrenia, as published in JAMA Psychiatry. The NOVA-1 trial demonstrated significant clinical improvements and a favorable safety profile. LB-102, a derivative of amisulpride, could become the first benzamide antipsychotic available in the U.S. The company is advancing to Phase 3 trials and exploring LB-102 for bipolar depression and other neuropsychiatric conditions. Topline results from the Phase 3 trial are expected in late 2027, with plans to discuss regulatory pathways with the FDA.

nasdaq

Nasdaq

LB Pharmaceuticals Reports Positive Phase 2 Results For LB-102 Published In JAMA Psychiatry

LB Pharmaceuticals (NASDAQ:LBRX) reached a new 52-week high of $32.49 during trading, closing at $31.67. Analysts have raised price targets, with Stifel Nicolaus increasing theirs from $35.00 to $40.00, maintaining a "buy" rating. The stock has a consensus rating of "Moderate Buy" and an average target price of $35.25. The company reported earnings of ($0.45) per share, meeting expectations. Institutional investors have recently increased their stakes in LB Pharmaceuticals, which focuses on developing therapies for neuropsychiatric diseases.

Market Beat

Stifel Financial

Bank of America

STIFEL FINANCIAL CORP 6.125% DEP SHS REP 1/1000 NON CU PF SR C

Stifel Financial Pref Share SFB 5.2 10/15/47

STIFEL FINANCIAL CORP 6.25%NON CUM DEP SHS REP 1/1000TH SER B

STIFEL FINANCIAL CORP 4.50% DEP SHS REP 1/1000TH PREF SHS SR D

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

LB Pharmaceuticals (NASDAQ:LBRX) Sets New 52-Week High  - Time to Buy?

Roth MKM analyst Boobalan Pachaiyappan has reiterated a Buy rating on LB Pharmaceuticals, Inc. (LBRX) with a price target of $31.00. Pachaiyappan, a 4-star analyst with an average return of 8.8% and a 45.45% success rate, focuses on the Healthcare sector. Additionally, Craig-Hallum also initiated coverage with a Buy rating and a $36.00 price target on the same stock.

Capricor Therap

NeuroSense Therapeutics - Unit

PolyPid

NEUROSENSE THERAPEUTICS LTD C/WTS 10/11/2026 (TO PUR COM)

LB Pharmaceuticals, Inc. (LBRX) Gets a Buy from Roth MKM

LSL Pharma’s Juno OTC Expands Allergy Portfolio With New Loratadine RDT Deal

LSL Pharma’s Juno OTC Expands Allergy Portfolio With New Loratadine RDT Deal

LB Pharmaceuticals(LBRX.US)

Craig-Hallum Keeps Their Buy Rating on LB Pharmaceuticals, Inc. (LBRX)

LB Pharmaceuticals | 8-K: FY2026 Q1 Revenue: USD 0

LTR Pharma Unveils Strong SPONTAN Data and Dual US Strategy

BioLineRx shares are trading higher after the company announces that the first patient has been dosed in its Phase 1/2A study of GLIX-1 for glioblastoma and other high-grade gliomas.

This LB Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

LB Pharmaceuticals Reports Positive Phase 2 Results For LB-102 Published In JAMA Psychiatry

LB Pharmaceuticals (NASDAQ:LBRX) Sets New 52-Week High - Time to Buy?

LB Pharmaceuticals, Inc. (LBRX) Gets a Buy from Roth MKM

LSL Pharma’s Juno OTC Expands Allergy Portfolio With New Loratadine RDT Deal